O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
Title:
O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
Author:
Kristeleit, R. Lisyanskaya, A. Fedenko, A. Dvorkin, M. De Melo, A.C. Shparyk, Y. Rakhmatullina, I. Bondarenko, I. Colombo, N. Svintsitskiy, V. Biela, L. Nechaeva, M. Raspagliesi, F. Scambia, G. Cibula, D. Póka, R. Oaknin, A. Safra, T. Mackowiak-Matejczyk, B. Ma, L.
Appeared in:
International journal of gynecological cancer
Paging:
Volume 31 () nr. S4 pages A5-A6
Year:
2021
Contents:
Publisher:
IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.